When is Wegovy coming to the UK — and what's already available?

Step 1, The injection arrived in 2023 (here's what that unlocked)

Novo Nordisk launched the Wegovy injection in the UK in September 2023, following MHRA licensing. The weekly subcutaneous injection uses semaglutide, a GLP-1 receptor agonist that works by mimicking a gut hormone involved in appetite regulation, slowing gastric emptying and reducing how hungry you feel between meals. The licensed starting dose is 0.25mg, titrated roughly every four weeks by your prescriber, with 2.4mg as the standard maintenance dose, a schedule detailed in full on the Wegovy treatment overview.

In the STEP 1 trial (68 weeks, adults with obesity), participants on semaglutide 2.4mg lost an average of around 15% of their body weight, as reported in the NEJM's publication of the STEP 1 results. That figure, combined with a strong safety profile, underpinned NICE's recommendation (TA875, published March 2023), though NICE limits NHS use to a maximum of two years within specialist weight management services.

Supply was patchy in the early months, as global demand outstripped manufacturing. That situation has improved significantly through 2024 and 2025, and for most doses availability through private routes is now reliable.

Step 2, 2026 brought a higher dose and an entirely new format

The story of when Wegovy is coming to the UK didn't end at launch. Two major developments landed in 2026. First, the MHRA approved a 7.2mg maintenance dose in January 2026 (initially delivered as three 2.4mg pens per week) before approving a dedicated single-dose 7.2mg pen on 14 April 2026. This pen has an auto-dosing mechanism, a built-in covered needle and locks after use. It is licensed for adults with a BMI of 30 or above only, and the titration schedule still starts at 0.25mg. Trials reported average weight loss of around 20.7% over 72 weeks at 7.2mg, which puts its results closer to those seen with tirzepatide at high doses. You can read more about how both injectable options compare on our semaglutide treatment page.

Second, on 11 June 2026, the MHRA approved the Wegovy tablet, making the UK the first country in Europe to licence an oral GLP-1 medicine specifically for weight management. The tablet uses semaglutide co-formulated with an absorption enhancer and is taken once daily on an empty stomach with a small amount of plain water, at least 30 minutes before food or other medicines. No refrigeration is needed, which matters for travel and daily routine. The OASIS 4 phase-3 trial (64 weeks, 307 adults without diabetes) reported an average weight loss of around 13.6% versus roughly 2.4% on placebo. Among participants who adhered fully throughout the trial, that figure rose to approximately 17%, though that higher number reflects full adherence, not the overall average.

If you're weighing up whether the injection or the tablet suits your life better, the practical guide to managing your Wegovy treatment covers what day-to-day use looks like for both formats.

Step 3, Understanding NHS access versus the private route

There's a gap between what's licensed and what's easy to access through the NHS, and it's worth being straight about that. NICE's recommendation for Wegovy (TA875) restricts NHS prescribing to patients within specialist weight management services, with at least one weight-related comorbidity and a BMI of 35 or above (lower thresholds apply for some ethnic backgrounds). Treatment is capped at two years. Waiting lists for these services are often long, and not every area has the same capacity.

Most people asking when is Wegovy coming to the UK are effectively asking whether they can access it now without a lengthy wait. The answer is yes, through a private prescription from a GPhC-registered pharmacy. The licensed eligibility criteria for private prescribing follow the medicine's SmPC: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes. A prescriber assesses your full picture; BMI alone doesn't determine suitability. You can check what's involved via our guide on where to buy Wegovy in the UK, which explains how to verify any pharmacy on the GPhC register before you proceed.

For context on how pricing works privately (including what a legitimate quote should cover) the weight-loss treatment overview sets out the honest picture. The NICE guidance for semaglutide (TA875) is also publicly available if you want to read the NHS access criteria directly.

Step 4 (What to do if you're ready to explore treatment now

If you've been waiting for Wegovy to become available in the UK, it already has) in more forms than most people realise. The practical questions at this point are about eligibility, format and clinical suitability. That's genuinely what a consultation is for. A prescriber can look at your health history, current BMI, any relevant conditions and whether the injection or the tablet is the better starting point for you.

It's understandable to feel impatient. Many people have watched friends or family access these medicines through the NHS while being told they don't quite meet the threshold, or that the wait is indeterminate. Private treatment through a regulated pharmacy is a legitimate path, provided the pharmacy is GPhC-registered and the prescription comes from a qualified independent prescriber reviewing your case personally, not a checkbox form routed to an algorithm.

If you're thinking about what happens further down the line (how long to stay on treatment, or what the process looks like when you come off) the guide to stopping Wegovy and the question of when to stop treatment are worth reading before you start. Decisions about stopping are made with your prescriber, not unilaterally, and understanding that process upfront tends to make the whole journey less uncertain.

Speak to our prescribers through a free consultation if you'd like to find out whether Wegovy is clinically suitable for you.